Record · verywellhealth.com
HER2-Low Breast Cancer Treatment
verywellhealth.com · 12 September 2026 · 6 min read
A post on verywellhealth.com, published 12 September 2026, has not been cited by any blog yet (corpus.blog, measured 16 October 2026).
A record is what was published and who pointed at it. The text of the post is not shown here: read it at the source, or at its Wayback capture.
0blogs citing
| Period | Blogs | Links |
|---|---|---|
| All time | 0 | 0 |
| Last 90 days | 0 | 0 |
| Last 30 days | 0 | 0 |
| Last 7 days | 0 | 0 |
| Words blogs link it with | 0 |
|---|---|
| External links | 0 |
| Length | 1,161 |
Cited by
No blog we hold has cited this post yet.
Links from this post
This post only links within verywellhealth.com.
Elsewhere on verywellhealth.com (18)
Similar posts
HERTHENA-Breast03: A phase 2, randomized, open-label study evaluating neoadjuvant patritumab deruxtecan + pembrolizumab before or after pembrolizumab + chemotherapy for early-stage TNBC or HR-low+/HER2− breast cancer.
$whoami : echo “tp53(ashish), ml + {medicine, biology} tinkerer” - tp53(ashish)’s home on the interwebs
30 Sept 2026
Efficacy and safety of disitamab vedotin in combination with RC148 versus albumin-bound paclitaxel ± toripalimab for patients with HR-negative HER2-low-expressing unresectable locally advanced or metastatic breast cancer: An open-label, randomized, controlled phase II study.
$whoami : echo “tp53(ashish), ml + {medicine, biology} tinkerer” - tp53(ashish)’s home on the interwebs
30 Sept 2026
24 Aug 2026
A randomized trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer (ARIADNE).
$whoami : echo “tp53(ashish), ml + {medicine, biology} tinkerer” - tp53(ashish)’s home on the interwebs
30 Sept 2026
The SURVIVE HERoes study: Targeting molecular relapse in breast cancer—A secondary adjuvant intervention study of trastuzumab deruxtecan versus SOC treatment in patients with HER2-positive or HER2-low early breast cancer and ctDNA positivity after primary therapy.
$whoami : echo “tp53(ashish), ml + {medicine, biology} tinkerer” - tp53(ashish)’s home on the interwebs
30 Sept 2026
Integrating gene signatures to guide HR+/HER2- MBC therapy in a diverse cohort (INSIGHT).
$whoami : echo “tp53(ashish), ml + {medicine, biology} tinkerer” - tp53(ashish)’s home on the interwebs
30 Sept 2026
LITESPARK-029: A phase 2, randomized, open-label study of belzutifan plus fulvestrant in participants with estrogen receptor–positive, HER2-negative unresectable locally advanced or metastatic breast cancer after progression on previous endocrine therapy.
$whoami : echo “tp53(ashish), ml + {medicine, biology} tinkerer” - tp53(ashish)’s home on the interwebs
30 Sept 2026
Phase IB/II study to evaluate safety and preliminary efficacy of the WEE1 inhibitor Debio 0123 in combination with sacituzumab govitecan (SG) in triple-negative or hormone receptor–positive (HR+)/HER2-negative (HER2–) advanced breast cancer (ABC): The WIN-B study.
$whoami : echo “tp53(ashish), ml + {medicine, biology} tinkerer” - tp53(ashish)’s home on the interwebs
30 Sept 2026
SOLTI-2201 ACROSS-TROP2 trial: A phase II study to identify predictive biomarkers of sacituzumab govitecan benefit and to understand resistance mechanisms in HR+/HER2- advanced or metastatic breast cancer.
$whoami : echo “tp53(ashish), ml + {medicine, biology} tinkerer” - tp53(ashish)’s home on the interwebs
30 Sept 2026
Looking for more like this? Find posts and blogs like it
Something wrong here? Report a problem